Logo image of PLX

PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Price, Quote, News and Overview

NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD

1.56  -0.06 (-3.7%)

After market: 1.6298 +0.07 (+4.47%)

PLX Quote, Performance and Key Statistics

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (5/27/2025, 8:04:01 PM)

After market: 1.6298 +0.07 (+4.47%)

1.56

-0.06 (-3.7%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.1
52 Week Low0.82
Market Cap124.19M
Shares79.61M
Float71.33M
Yearly DividendN/A
Dividend YieldN/A
PE39
Fwd PE1.84
Earnings (Next)08-12 2025-08-12
IPO09-06 2010-09-06


PLX short term performance overview.The bars show the price performance of PLX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

PLX long term performance overview.The bars show the price performance of PLX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20

The current stock price of PLX is 1.56 USD. In the past month the price decreased by -45.26%. In the past year, price increased by 38.05%.

PROTALIX BIOTHERAPEUTICS INC / PLX Daily stock chart

PLX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.08 328.06B
AMGN AMGEN INC 13.46 150.26B
GILD GILEAD SCIENCES INC 14.09 135.70B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.53B
REGN REGENERON PHARMACEUTICALS 13.61 65.13B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.83B
ARGX ARGENX SE - ADR 98.77 35.40B
ONC BEIGENE LTD-ADR 6.1 25.76B
BNTX BIONTECH SE-ADR N/A 23.69B
NTRA NATERA INC N/A 21.46B
SMMT SUMMIT THERAPEUTICS INC N/A 19.04B
BIIB BIOGEN INC 8.12 18.81B

About PLX

Company Profile

PLX logo image Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 207 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Company Info

PROTALIX BIOTHERAPEUTICS INC

2 University Plaza, Suite 100

Hackensack NEW JERSEY 07601 US

CEO: Dror Bashan

Employees: 213

PLX Company Website

PLX Investor Relations

Phone: 12016969345

PROTALIX BIOTHERAPEUTICS INC / PLX FAQ

What is the stock price of PROTALIX BIOTHERAPEUTICS INC today?

The current stock price of PLX is 1.56 USD. The price decreased by -3.7% in the last trading session.


What is the ticker symbol for PROTALIX BIOTHERAPEUTICS INC stock?

The exchange symbol of PROTALIX BIOTHERAPEUTICS INC is PLX and it is listed on the NYSE Arca exchange.


On which exchange is PLX stock listed?

PLX stock is listed on the NYSE Arca exchange.


What is the price forecast or stock price prediction for PROTALIX BIOTHERAPEUTICS INC stock?

5 analysts have analysed PLX and the average price target is 14.79 USD. This implies a price increase of 848.08% is expected in the next year compared to the current price of 1.56. Check the PROTALIX BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PROTALIX BIOTHERAPEUTICS INC worth?

PROTALIX BIOTHERAPEUTICS INC (PLX) has a market capitalization of 124.19M USD. This makes PLX a Micro Cap stock.


How many employees does PROTALIX BIOTHERAPEUTICS INC have?

PROTALIX BIOTHERAPEUTICS INC (PLX) currently has 213 employees.


What are the support and resistance levels for PROTALIX BIOTHERAPEUTICS INC (PLX) stock?

PROTALIX BIOTHERAPEUTICS INC (PLX) has a support level at 1.49 and a resistance level at 1.72. Check the full technical report for a detailed analysis of PLX support and resistance levels.


Is PROTALIX BIOTHERAPEUTICS INC (PLX) expected to grow?

The Revenue of PROTALIX BIOTHERAPEUTICS INC (PLX) is expected to grow by 61.73% in the next year. Check the estimates tab for more information on the PLX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PROTALIX BIOTHERAPEUTICS INC (PLX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PROTALIX BIOTHERAPEUTICS INC (PLX) stock pay dividends?

PLX does not pay a dividend.


When does PROTALIX BIOTHERAPEUTICS INC (PLX) report earnings?

PROTALIX BIOTHERAPEUTICS INC (PLX) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of PROTALIX BIOTHERAPEUTICS INC (PLX)?

The PE ratio for PROTALIX BIOTHERAPEUTICS INC (PLX) is 39. This is based on the reported non-GAAP earnings per share of 0.04 and the current share price of 1.56 USD. Check the full fundamental report for a full analysis of the valuation metrics for PLX.


What is the Short Interest ratio of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?

The outstanding short interest for PROTALIX BIOTHERAPEUTICS INC (PLX) is 1.48% of its float. Check the ownership tab for more information on the PLX short interest.


PLX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to PLX. When comparing the yearly performance of all stocks, PLX turns out to be only a medium performer in the overall market: it outperformed 59.3% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PLX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to PLX. PLX has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PLX Financial Highlights

Over the last trailing twelve months PLX reported a non-GAAP Earnings per Share(EPS) of 0.04. The EPS decreased by 0% compared to the year before.


Industry RankSector Rank
PM (TTM) 6.54%
ROA 5.29%
ROE 8.64%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%16.67%
Sales Q2Q%169.68%
EPS 1Y (TTM)0%
Revenue 1Y (TTM)0.18%

PLX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to PLX. The Buy consensus is the average rating of analysts ratings from 5 analysts.

For the next year, analysts expect an EPS growth of 943.67% and a revenue growth 61.73% for PLX


Ownership
Inst Owners6.74%
Ins Owners7.79%
Short Float %1.48%
Short Ratio1.03
Analysts
Analysts80
Price Target14.79 (848.08%)
EPS Next Y943.67%
Revenue Next Year61.73%